Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Leiomyoma 2Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2 1Uterine Hemorrhage 1Prostatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Cushing Syndrome 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1ACTH Syndrome, Ectopic 1

Interventions

relacorilant 2Osilodrostat 2Metyrapone 2Observation 1Mifepristone 1Adrenalectomy 1Abiraterone Acetate 1ASP3662 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cushing Syndrome × Mifepristone × Clear all
NCT00422201 2019-10-11

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

HRA Pharma

Phase 2 Terminated
18 enrolled 9 charts

ACTH Syndrome, Ectopic, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡